Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection

Rau, Monika; Stickel, Felix; Russmann, Stefan; Manser, Christine N; Becker, Philip P; Weisskopf, Michael; Schmitt, Johannes; Dill, Michael T; Dufour, Jean-François; Moradpour, Darius; Semela, David; Müllhaupt, Beat; Geier, Andreas; Swiss Hepatitis C Cohort Study Group (SCCS), (2013). Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. Journal of hepatology, 58(4), pp. 669-75. Amsterdam: Elsevier 10.1016/j.jhep.2012.11.027

Full text not available from this repository. (Request a copy)

In the last decade, pegylated interferon-α (PegIFN-α) plus ribavirin (RBV) was the standard treatment of chronic hepatitis C for genotype 1, and it remains the standard for genotypes 2 and 3. Recent studies reported associations between RBV-induced anemia and genetic polymorphisms of concentrative nucleoside transporters such as CNT3 (encoded by SLC28A3) and inosine triphosphatase (encoded by ITPA). We aimed at studying genetic determinants of RBV kinetics, efficacy and treatment-associated anemia.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology

UniBE Contributor:

Stickel, Felix and Dufour, Jean-François

ISSN:

0168-8278

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:38

Last Modified:

17 Mar 2015 21:30

Publisher DOI:

10.1016/j.jhep.2012.11.027

PubMed ID:

23195617

Web of Science ID:

000317375600006

URI:

https://boris.unibe.ch/id/eprint/15201 (FactScience: 222493)

Actions (login required)

Edit item Edit item
Provide Feedback